~~AMENDED~~ CLAIMS

~~received by the International Bureau on 12 DEC 2012 (12.12.2012)~~

1. A process for preparing fluticasone propionate as crystalline polymorphic form 1 characterized in that it comprises the step of dissolving fluticasone propionate in a solvent to form a solution, and then adding the solution to a water-containing non-solvent, thereby causing fluticasone propionate to crystallise out of the solution as crystalline form 1;

wherein the solvent comprises acetone and from 0% to 10% water, based on the volume of the solvent; and

wherein the non-solvent comprises water and from 0% to 35% acetone, based on the volume of the non-solvent.

2. A process according to claim 1, wherein fluticasone propionate is dissolved in the solvent in an amount between 30 and 50 grams per litre of solvent.

3. A process according to claim 1, wherein fluticasone propionate is dissolved in a first defined volume of the solvent to form a solution, and the solution is then added to a second defined volume of the non-solvent;

a ratio of the first defined volume to the second defined volume being between 1:0.65 and 1:1.35.

4. A process according to claim 2, wherein fluticasone propionate is dissolved in a first defined volume of the solvent to form a solution, and the solution is then added to a second defined volume of the non-solvent;

a ratio of the first defined volume to the second defined volume being between 1:0.65 and about 1:1.35.

5. A process according to claim 1, claim 2, claim 3, or claim 4, wherein said adding the solution takes place at a temperature between about 10°C and about 40°C.

6. A process according to claim 1, claim 2, claim 3, or claim 4, wherein said adding the solution takes place over a period of between about 10 minutes and about 6 hours.

7. A process according to claim 5, wherein said adding the solution takes place over a period of between about 10 minutes and about 6 hours.

8. A process according to claim 1, claim 2, claim 3, or claim 4, wherein said adding the solution occurs via a pump in the form of pulsed aliquots.

9. A process according to claim 1, claim 2, claim 3, or claim 4, wherein said adding the solution occurs over a period of between about 10 minutes and about 6 hours via a pump in the form of pulsed aliquots.

10. A process according to claim 1, claim 2, claim 3, or claim 4, wherein once the step of adding the solution to the non-solvent is completed, a slurry forms and the slurry is stirred over a period of between 0 and about 12 hours,

followed by filtration of the slurry to recover fluticasone propionate as crystalline form 1 and drying of the recovered fluticasone propionate.

11. A process according to claim 5, wherein once the step of adding the solution to the non-solvent is completed, a slurry forms and the slurry is stirred over a period of between 0 and about 12 hours, followed by filtration of the slurry to recover fluticasone propionate as crystalline form 1 and drying of the recovered fluticasone propionate.

12. A process according to 7, wherein once the step of adding the solution to the non-solvent is completed, a slurry forms and the slurry is stirred over a period of between 0 and about 12 hours, followed by filtration of the slurry to recover fluticasone propionate as crystalline form 1 and drying of the recovered fluticasone propionate.

13. A process according to claim 8, wherein once the step of adding the solution to the non-solvent is completed, a slurry forms and the slurry is stirred over a period of between 0 and about 12 hours, followed by filtration of the slurry to recover fluticasone propionate as crystalline form 1 and drying of the recovered fluticasone propionate.

14. Fluticasone propionate form 1, wherein said fluticasone propionate form 1 is obtained by a process according to according to claim 1, claim 2, claim 3, or claim 4,

wherein said fluticasone propionate form 1 is characterized by each of the following:

~~has~~ particles having a median particle size of between 5 microns and 35 microns~~.~~;

particles which do not exhibit agglomeration; and

particles which are between 5 and 200 microns in length, and between 3 and 30 microns in width.

~~15. Fluticasone propionate form 1, wherein said fluticasone propionate form 1 is obtained in the form of particles by a process according to according to claim 1, claim 2, claim 3, or claim 4,~~

~~wherein said particles do not exhibit agglomeration.~~

~~16. Fluticasone propionate form 1, wherein said fluticasone propionate form 1 is obtained in the form of particles by a process according to according to claim 1, claim 2, claim 3, or claim 4,~~

~~wherein said particles are between 5 and 200 microns in length, and have a width of between 3 and 30 microns.~~